Skip to main content
Premium Trial:

Request an Annual Quote

Illumina: Susan Tousi, Alex Aravanis

Illumina has appointed Susan Tousi as chief commercial officer and has given CTO Alex Aravanis additional duties related to research and product development.

Tousi has led Illumina's global product development since 2012. Prior to joining Illumina, she was corporate VP and general manager for Eastman Kodak's consumer inkjet systems business. She holds an MBA from the University of California, Los Angeles.

Aravanis will take over product development in addition to his duties as CTO. He began at Illumina in 2013 and left in 2016 to cofound liquid biopsy firm Grail, where he was chief scientific officer and head of R&D. Aravanis rejoined Illumina in June 2020 as CTO (Illumina is trying to acquire Grail for about $8 billion, a move that the US Federal Trade Commission has challenged). He holds an MD and doctorate in electrical engineering from Stanford University.

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.